Trial · NCT02786277
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Patients With Progression to a Higher Stage of AKI OR Dialysis OR Death | Recommended | 190 | Participants | ||
| Proportion of Patients With Progression to a Higher Stage of AKI OR Dialysis OR Death | Anti-recommended | 193 | Participants | ||
| 14-day Mortality | Recommended | 72 | Participants | ||
| 14-day Mortality | Anti-recommended | 58 | Participants | ||
| Inpatient Mortality | Recommended | 169 | Participants | ||
| Inpatient Mortality | Anti-recommended | 185 | Participants | ||
| 14-day Dialysis | Recommended | 38 | Participants | ||
| 14-day Dialysis | Anti-recommended | 37 | Participants | ||
| Inpatient Dialysis | Recommended | 39 | Participants | ||
| Inpatient Dialysis | Anti-recommended | 41 | Participants | ||
| Discharge on Dialysis | Recommended | 28 | Participants | ||
| Discharge on Dialysis | Anti-recommended | 22 | Participants | ||
| Progression to Stage 2 AKI | Recommended | 91 | Participants | ||
| Progression to Stage 2 AKI | Anti-recommended | 103 | Participants | ||
| Progression to Stage 3 AKI | Recommended | 72 | Participants | ||
| Progression to Stage 3 AKI | Anti-recommended | 66 | Participants | ||
| Duration of AKI | Recommended | 26.9 | Inter-Quartile Range 22.5 to 50.1 | Hours | |
| Duration of AKI | Anti-recommended | 27.7 | Inter-Quartile Range 22.3 to 50.6 | Hours | |
| 30 Day Readmission Rate | Recommended | 123 | Participants | ||
| 30 Day Readmission Rate | Anti-recommended | 187 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02786277/results